Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3493-3498

  Krug, L M ^a   Ng, K K ^a   Kris, M G ^a   Miller, V A ^a   Tong, W ^a   Heelan, R T ^a   Leon, L ^a   Leung, D ^a   Kelly, J ^a   Sirotnak, F M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 10 DEAZAAMINOPTERIN; ANTINEOPLASTIC AGENT; FOLIC ACID ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG URINE LEVEL; EPISTAXIS; FEMALE; HUMAN; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

AMINOPTERIN; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLIC ACID ANTAGONISTS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 0033818197     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. New folate analogues of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties
2. New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models
3. New folate analogs of the 10-deaza-aminopterin series. Markedly increased activity of the 10-ethyl analogue compared to the parent compound and methotrexate against some human tumor xenografts in nude mice
4. Phase II study of 10-ethyI-10-deaza-aminopterin in patients with stage III and IV non-small cell lung cancer
5. Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIb or IV non-small cell lung cancer
6. Phase II study of edatrexate in stage III and IV non-small-cell lung cancer
7. Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer
8. Phase II study of weekly edatrexate as first line chemotherapy for metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study
9. Edatrexate (10-ethyl-deaza-aminopterin) (NSC 626715) with or without leucovorin rescue for malignant mesothelioma. Sequential Phase II trials by the Cancer and Leukemia Group B
10. Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma
11. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice
12. Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin
13. Fluorometric HPLC analysis of 10-deazaaminopterin, 10-ethyl-10-deazaaminopterin and known metabolites
14. Limited-sampling models for anticancer agents
15. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer
16. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines
17. Schedule-dependent synergism of Taxol or Taxotere with edatrexate against human breast cancer cells in vitro
18. A Phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors
19. Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors
20. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer
21. Energy dependent efflux of methotrexate in L1210 leukemia cells. Evidence for a role of an ATPase obtained with inside-out plasma membrane vesicles
22. Improved methotrexate therapy of murine tumors obtained by probenecid-mediated pharmacological modulation at the level of membrane transport
23. Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferential inhibition of efflux
24. Coadministration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo